All In Biotech

Drug Trial Radar · NCT05814666

Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

An Open-Label, Phase II, Randomized, Controlled Study of Danvatirsen Plus Pembrolizumab Compared to Pembrolizumab Alone in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Last checked: Nov 19, 2026Latest source record: Jan 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

69

Actual

Start

May 30, 2023

Primary completion

Aug 14, 2025

Study completion Aug 14, 2025

Sponsor

Lead sponsor
Flamingo Therapeutics NVIndustry
Sponsor type
Industry
First posted
Apr 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open-label, Phase II, randomized, controlled study evaluating the efficacy and safety of danvatirsen in combination with pembrolizumab compared with pembrolizumab alone as first-line treatment of patients with recurrent/metastatic (R/M) HNSCC. Two-thirds of patients will be randomized to receive danvatirsen and pembrolizumab and one-third will be randomized to receive pembrolizumab alone.

Conditions

  • HNSCC

Interventions

  • DanvatirsenDrug

    Danvatirsen is a STAT3 targeting drug.

  • PembrolizumabDrug

    Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Confirmed ORRTime frame: Up to 18 months

Locations

32 sites in 3 countries. Site status is shown where the registry gives one.

  • The University of Arizona Cancer Center

    Tucson, Arizona

  • University of California Irvine (UCI)

    Irvine, California

  • TMPN Hunt Cancer Care

    Torrance, California

  • University of California Los Angeles

    Westwood, Los Angeles, California

  • University of Colorado Hospital (UCH) Anschutz Cancer Pavilion

    Aurora, Colorado

  • Miami Cancer Institute

    Miami, Florida

  • Emory University Hospital Midtown

    Atlanta, Georgia

  • University of Illinois Cancer Center

    Chicago, Illinois

  • AMR Kansas City Oncology

    Merriam, Kansas

  • University of Kansas Medical Center

    Westwood, Kansas

  • Mary Bird Perkins Cancer Center

    Baton Rouge, Louisiana

  • University of Maryland Baltimore, Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Morristown Medical Center

    Morristown, New Jersey

  • Mount Sinai

    New York, New York

  • Stony Brook Cancer Center

    Stony Brook, New York

  • The Christ Hospital Cancer Center

    Cincinnati, Ohio

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

  • University Hospitals Cleveland

    Cleveland, Ohio

  • Prisma Health Cancer Institute

    Greenville, South Carolina

  • UT Southwestern Medical Center/Simmons Comprehensive Cancer Center

    Dallas, Texas

  • Dong-A University Hospital

    Busan, South Korea

  • Kosin University College of Medicine - Kosin University Gospel Hospital (KUGH)

    Busan, South Korea

  • Gyeongsang National University Hospital

    Jinju, South Korea

  • Korea University Medical Center (KUMC)

    Seoul, South Korea

  • The Catholic University of Korea - Eunpyeong St. Mary's Hospital

    Seoul, South Korea

  • Saint James's University Hospital (SJUH) - St James's Institute of Oncology

    Leeds, United Kingdom

  • The Clatterbridge Cancer Centre NHS Foundation Trust

    Liverpool, United Kingdom

  • Barts Health MHS Trust (Barts and The London NHS Trust) - St Bartholomew's (Barts) Hospital

    London, United Kingdom

  • The Royal Marsden NHS Foundation Trust

    London, United Kingdom

  • East and North Hertfordshire NHS Trust, Lister Hospital

    Northwood, United Kingdom

  • The Royal Marsden NHS Foundation Trust

    Sutton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.